Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: A randomized controlled trial

JAMA

Volumn 293, Issue 14, 2005, Pages 1751-1758

  Buttery, Jim P ^a,b,c,f   Riddell, Anna ^c   McVernon, Jodie ^c   Chantler, Tracey ^c   Lane, Laura ^c   Bowen Morris, Jane ^c   Diggle, Linda ^c   Morris, Rhonwen ^d   Harnden, Anthony ^c   Lockhart, Steven ^e   Pollard, Andrew J ^c   Cartwright, Keith ^d   Moxon, E Richard ^c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^e PFIZER INC   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE PLUS MENINGOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE TETANUS TOXIN CONJUGATE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE-TETANUS TOXIN CONJUGATE; HAEMOPHILUS VACCINE; VACCINE;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BACTERIAL MENINGITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG FEVER; DRUG SAFETY; EDEMA; ERYTHEMA; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFANT; IRRITABILITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS GROUP C; VACCINATION; VACCINATION REACTION; BIOSYNTHESIS; FEMALE; IMMUNOLOGY; MALE; NEISSERIA MENINGITIDIS; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, ORAL; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 20144389088     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.14.1751     Document Type: Article

References (23)

1. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717-722.
2. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
3. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
4. English M, MacLennan JM, Bowen-Morris JM, et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine. 2000;19:1232-1238.
5. Kayhty H. Immunogenicity assays and surrogate markers to predict vaccine efficacy. Dev Biol Stand. 1998;95:175-180.
6. Quataert S, Martin D, Anderson P, et al. A multilaboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest. 2001;30:191-207.
7. Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine. 2003;21:2190-2196.
8. Black S, Shinefield H, Fireman B, et al; Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
9. Dagan R, Kayhty H, Wuorimaa T, et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J. 2004;23:91-98.
10. Puumalainen T, Zeta-Capeding MR, Kayhty H, et al. Antibody response to an eleven valent diphtheria-and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr Infect Dis J. 2002;21:309-314.
11. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
12. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I: the role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
13. Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infed Immun. 2002;70:4946-4954.
14. Anderson P, Treanor J, Porcelli S, Pichichero M. Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children. Vaccine. 2003;21:1554-1559.
15. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a Haemophilus influenzae type fatetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J. 2000;19:1135-1140.
16. Barington T, Skettrup M, Juul L, Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun. 1993;61:432-438.
17. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284:2334-2340.
18. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367.
19. McVernon J, Maclennan J, Clutterbuck E, Buttery J, Moxon ER. Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in preschool aged children. Vaccine. 2003;21:2573-2579.
20. World Health Organization. Vaccine Research and Development Report of a Technical Review Group Meeting, June 9-70, 1997. Geneva, Switzerland: WHO; 1997:32-36.
21. Cronin WA, Germanson TP, Donowitz LG. Intravascular catheter colonization and related bloodstream infection in critically ill neonates. Infect Control Hosp Epidemiol. 1990;11:301-308.
22. Sleeman K, Knox K, George R, et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis. 2001;183:239-246.
23. Huebner RE, Wasas AD, Klugman KP. Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int J Infect Dis. 2000;4:214-218.